Mark D Pegram, MD
Stanford Cancer Institute, Stanford University Medical Center · Jonsson Comprehensive Cancer Center · University of California, Los Angeles
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark D Pegram, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:46 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00481845 · Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast CancerStanford University · terminated · Breast Cancer · principal investigator
- N/ANCT00433407 · T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid TumorsJonsson Comprehensive Cancer Center · completed · Breast Cancer, Lung Cancer, Ovarian Cancer · study chair
- Ph1NCT00349167 · PR-104 in Treating Patients With Advanced Solid TumorsProacta, Incorporated · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph2NCT00096239 · CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerJonsson Comprehensive Cancer Center · completed · Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer · principal investigator
- Ph1NCT00096057 · Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast CancerJonsson Comprehensive Cancer Center · completed · Breast Cancer · study chair
- Ph1/Ph2NCT00095706 · Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)Translational Oncology Research International · completed · Breast Cancer · principal investigator
- Ph1NCT00093730 · BMS-599626 in Treating Patients With Metastatic Solid TumorsJonsson Comprehensive Cancer Center · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph1NCT00085020 · GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/NeuJonsson Comprehensive Cancer Center · completed · Breast Cancer · principal investigator
- Ph1/Ph2NCT00066547 · Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination ChemotherapyJonsson Comprehensive Cancer Center · unknown · Breast Cancer · principal investigator
- Ph1/Ph2NCT00031616 · NB1011 in Treating Patients With Metastatic or Recurrent Colorectal CancerNewBiotics · unknown · Colorectal Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center Administration (Admin)P30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Melissa Fitzmaurice Neligan · fiscal years 1997 to 2026Named on NCT00349167
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.